| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 326,5 k € | -4.0% | 340,1 k € | -16.3% | 406,2 k € | +96.0% | 207,2 k € | +3.4% | 200,5 k € | -21.2% | 254,3 k € | +35.5% | 187,6 k € | +5.6% | 177,7 k € | +10.6% | 160,8 k € | +5.4% | 152,6 k € | +56.4% | 97,6 k € | -55.6% | 219,9 k € | |
| EBITDA | 325,0 k € | -3.9% | 338,0 k € | -16.3% | 403,7 k € | +97.4% | 204,5 k € | +2.8% | 199,0 k € | -21.3% | 252,9 k € | +35.7% | 186,3 k € | +6.0% | 175,7 k € | +10.4% | 159,2 k € | +5.3% | 151,2 k € | +57.2% | 96,2 k € | -55.7% | 217,0 k € | |
| Operating profit | 299,3 k € | -9.5% | 330,6 k € | -17.9% | 402,6 k € | +144.4% | 164,8 k € | +13.8% | 144,7 k € | -27.2% | 198,9 k € | +50.3% | 132,4 k € | +7.8% | 122,8 k € | +18.1% | 104,0 k € | +0.9% | 103,0 k € | +118.8% | 47,1 k € | -59.4% | 115,9 k € | |
| Profit/loss | 219,5 k € | -9.4% | 242,2 k € | -14.1% | 281,9 k € | +143.1% | 115,9 k € | +11.3% | 104,1 k € | -24.9% | 138,6 k € | +52.7% | 90,8 k € | +8.1% | 84,0 k € | +32.7% | 63,3 k € | +1.7% | 62,2 k € | +99.4% | 31,2 k € | -55.4% | 70,1 k € | |
| Equity | 961,8 k € | -8.6% | 1,1 M € | +17.7% | 893,6 k € | +32.4% | 675,1 k € | +8.6% | 621,4 k € | +8.5% | 572,5 k € | +32.0% | 433,8 k € | +7.4% | 403,8 k € | +26.3% | 319,8 k € | +24.7% | 256,5 k € | +32.0% | 194,3 k € | +19.1% | 163,1 k € | |
| Total assets | 1,0 M € | -9.6% | 1,2 M € | +19.1% | 970,6 k € | +38.3% | 701,7 k € | +11.3% | 630,4 k € | +4.8% | 601,6 k € | +9.6% | 549,0 k € | +6.2% | 517,2 k € | +4.4% | 495,3 k € | +19.0% | 416,0 k € | +5.2% | 395,5 k € | -3.1% | 408,1 k € | |
| Cash | 27,1 k € | -62.8% | 72,8 k € | -57.7% | 172,2 k € | -64.3% | 481,9 k € | -0.2% | 482,6 k € | +19.3% | 404,5 k € | +56.9% | 257,8 k € | -13.9% | 299,5 k € | +23.9% | 241,7 k € | +41.4% | 170,9 k € | +258.6% | 47,7 k € | +67.2% | 28,5 k € | |
| Debts | 82,9 k € | -20.2% | 103,8 k € | +35.9% | 76,4 k € | +193.8% | 26,0 k € | +189.0% | 9,0 k € | -68.5% | 28,6 k € | -75.2% | 115,2 k € | +1.6% | 113,4 k € | -35.4% | 175,4 k € | +10.0% | 159,5 k € | -20.7% | 201,2 k € | -17.9% | 245,1 k € | |
Private limited company · Merelbeke-Melle · incorporated on 07/01/2013
Private limited company profitable and well capitalised. Cash position declining (-62.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Dr. Caroline Lamot Oncologie is a Private limited company incorporated in 2013. Its registered office is in Merelbeke-Melle.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette